(Q36530231)

14 August 2017

1 reference

title

Therapeutic lymphoma vaccines: importance of T-cell immunity (English)

1 reference

14 August 2017

1

Sattva S Neelapu

1 reference

14 August 2017

Seung-Tae Lee

2

1 reference

14 August 2017

Hong Qin

3

1 reference

14 August 2017

Soung-Chul Cha

4

1 reference

14 August 2017

Alison F Woo

5

1 reference

14 August 2017

Larry W Kwak

6

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Expert Review of Vaccines

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

381-394

1 reference

Follicular lymphoma: time for a re-think?

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Antibody to a molecularly-defined antigen confined to a tumour cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

GM-CSF gene-transduced tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

B cells directly tolerize CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Targeting the innate immune response with improved vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

The enemy within: keeping self-reactive T cells at bay in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.3.381

21 January 2018

Identifiers

DOI

10.1586/14760584.5.3.381

1 reference

14 August 2017

1 reference